InvestorWire NewsRoom


CannAssist International Corp. (CNSC) Flagship Brand Approved, Included by Powerful Online Platform
January 7, 2021

CannAssist International Corp. (CNSC) Flagship Brand Approved, Included by Powerful Online Platform

  • Acceptance of Xceptol products on RangeMe website new revenue source, increasing SKUs and access to retailers
  • RangeMe enables retail buyers to discover innovative, emerging products; empowers suppliers to manage, grow their brands
  • CannAssist developed Xceptol brand to offer effective health and wellness solutions without side effects

CannAssist International (OTCQB: CNSC) has announced that its flagship brand — Xceptol — has been approved and included by the distribution website RangeMe ( Xceptol’s inclusion on the website means increasing SKUs, access to more than 10,000 retailers, and a significant new revenue source for CNSC.

“This is exciting news for us on many fronts,” said CannAssist CEO Mark Palumbo. “A process estimated to take weeks was accomplished in a few days — a testament, I feel, to the quality of the Xceptol brand. Also gratifying is being included on the RangeMe website, a significant portal for major retailers to find products for their customers.” 

RangeMe is an online platform that enables retail buyers to efficiently discover innovative and emerging products while empowering suppliers to manage and grow their brands with the tools, insights, and services they need. In the announcement, CNSC noted that RangeMe had added Xceptol drops and capsules to the Xceptol pain-cream products that are available on the RangeMe platform.

The inclusion brings the number of available Xceptol SKUs on RangeMe to 10, with additional SKUs coming in Q1 2021. RangeMe’s broad network creates a significant new revenue source for CannAssist International. 

CannAssist developed its exclusive Xceptol brand, along with CiBiDinol or water-compatible cannabidiol, with the objective of offering powerful health and wellness solutions without troublesome side effects ( Team members had extensive experience and background with science, health care and conventional pharmaceutical therapies and recognized the need for a different approach to treatment of acute and chronic pain.

CannAssist experts began exploring ways to solve inherent issues with CBD delivery and bioavailability — CiBiDinol and the Xceptol brand are the result. Xceptol products feature CiBiDinol and offer better absorption than oil-based products currently available. CiBiDinol provides CBD in a format that is more in line with the body’s natural bioactivity and is specifically designed to tackle issues with oil-soluble CBD molecules, such as delivery, bioavailability and short shelf-life. Xceptol products also offer more predictable potency.

CNSC’s Xceptol Pain Cream is a CBD product with industry-defining reliability and compliance. Possessing a National Drug Code (“NDC”), the highest quality ingredients and the game-changing CiBiDinol, the pain cream is fast gaining attention in the pain-treatment space and is leading the way for other Xceptol products to follow. CannAssist believes Xceptol represents the next step for CBD products.

Established in 2017, CannAssist is headquartered in San Diego County, California, and is the owner of Xceptor Labs, a biotechnological pharmaceutical and wellness company. CannAssist is currently focused on marketing its Xceptol brand, which is why the RangeMe announcement is so significant.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).